home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login »

news

Mar2Pharmaceutical Industry Veteran and Pioneer Sidney Taurel Joins Capital Royalty as Senior Advisor


FORMER ELI LILLY & CO. CEO AND CHAIRMAN BRINGS GLOBAL HEALTHCARE INDUSTRY PERSPECTIVE, EXPERIENCE AND RELATIONSHIPS TO CAPITAL ROYALTY’S HEALTHCARE FINANCING TEAM.

 

Houston, TX - March 2, 2010 – Capital Royalty L.P. (“Capital Royalty”) announced today that effective immediately, Sidney Taurel, a recognized global pharmaceutical veteran and innovator, has joined the firm as a Senior Advisor. Mr. Taurel also will Chair Capital Royalty’s newly-established Strategic Advisory Committee (“SAC”).

 

Mr. Taurel brings a lifetime career of pharmaceutical industry experience and leadership, including 37 years at Eli Lilly and Co. where he served successively as President of Lilly International, President and Chief Operating Officer of the Company, and a decade as Chief Executive Officer and Chairman. A visionary and pioneer in transforming his own industry, Mr. Taurel was integral in shaping Lilly’s long-term future direction, including a strategic focus in building product pipelines through partnerships and licensing activities, many of which created large royalty streams.  Over his career, Mr. Taurel completed over $30 billion in acquisitions and licensing transactions.

 

As Senior Advisor, Mr. Taurel will support Capital Royalty’s efforts in sourcing new monetization opportunities, enhancing the Firm’s robust due diligence processes, evaluating potential investments, strengthening the Firm’s pharmaceutical and biotech industry relationships, and helping to shape the Firm’s vision and strategy to take advantage of emerging opportunities and trends created by the growth of and changes in the healthcare industry.

 

Mr. Taurel will also serve as the Chairman of Capital Royalty’s Strategic Advisory Committee created to support the Firm’s investment team in identifying emerging industry trends, strengthening industry relationships, evaluating potential new investments and pursuing new areas of opportunity. In his role as Chairman, Mr. Taurel will help identify and recruit world-class committee members including recognized global thought leaders and experts with complementary experience in scientific development, government reimbursement and healthcare regulatory policy. 

 

“Our stated goal is to strengthen and position Capital Royalty for market leadership in healthcare investing for the future. Our plan is three-fold:  assemble a world-class investment team that unites the finest pioneers and innovators in healthcare financing; sharpen our collective vision to enhance our competitive market advantage; and, refine our royalty investment strategy to attract the highest-quality IP assets through the design of innovative royalty financing structures,” said Charles W. Tate, Capital Royalty Founder and Chairman.

 

“We are gratified that the success of 2009’s strategic initiatives together with record investment performance generated by Capital Royalty’s assembled world-class team, has attracted the attention and commitment of Mr. Taurel, a giant in the pharmaceutical industry. Sidney brings a wealth of industry leadership, knowledge, experience and contacts as well as a strong commitment to support Capital Royalty’s future vision. He will be integral in helping shape and execute our vision for the future,” said Mr. Tate.

 

“It is an honor to have the opportunity to work with a team of this caliber to build the future success of Capital Royalty. The firm’s pioneering commitment to deliver the most cutting-edge and innovative healthcare financing to support our industry fits well with my background and views on the future of the pharmaceutical industry.  At Eli Lilly, I helped to lead the company and industry in its strategic transformation to increasingly build its product pipeline through partnering and licensing activities. Royalty transactions are now a core part of the industry’s long-term strategy and they will continue to create tremendous opportunities for both royalty sellers and their investors,” said Mr. Taurel. 

 

Over his career, Mr. Taurel has served on several global public and private corporate boards, including the Pharmaceutical Research and Manufacturers of America (PhRMA), the boards of both IBM Corporation and McGraw-Hill Companies, Inc, and the board of Overseers of the Columbia Business School. Mr. Taurel is a member of The Business Roundtable and the executive committee of The Business Council, as well as an integral part of the President's Homeland Security Advisory Council (2002-2004), the President's Export Council (2005-2006), and the Advisory Committee for Trade Policy and Negotiations.

 

ABOUT CAPITAL ROYALTY, L.P.

Founded in 2003, Capital Royalty L.P. is a market pioneer and innovator in healthcare investing with a focus on intellectual property investments in FDA-approved biopharmaceutical assets through royalty bond and other royalty monetization structures. Collectively, the Capital Royalty investment team has more than 140 years of healthcare, capital markets, private equity and investment banking experience, having completed more than 50 royalty transactions representing $3.7 billion in capital over the past fifteen years. Capital Royalty focuses on sourcing, structuring and investing in healthcare royalty monetization transactions that target attractive risk-adjusted returns with superior downside protection for investors.  The Firm is headquartered in Houston, Texas with offices in New York, New York and Boulder, Colorado.  For further information, please visit www.capitalroyalty.com.